Arcutis Biotherapeutics (ARQT) Short-term Investments (2019 - 2026)

Arcutis Biotherapeutics' Short-term Investments history runs 8 years deep, the most recent figure standing at $189.2 million for Q1 2026.

• In Q1 2026, Short-term Investments rose 30.52% year-over-year to $189.2 million; the TTM figure through Mar 2026 stood at $189.2 million (up 30.52% YoY), while the FY2025 annual figure was $178.1 million, up 13.7% from the prior year.
• Short-term Investments for Q1 2026 stood at $189.2 million, up from $178.1 million in the prior quarter.
• The five-year high for Short-term Investments was $395.4 million in Q3 2022, with the low at $118.1 million in Q2 2025.
• The 5-year median for Short-term Investments is $189.2 million (2026), against an average of $210.7 million.
• The sharpest annual moves came in 2022 and 2023: Short-term Investments surged 75.25% in 2022, then slumped 69.74% in 2023.
• Arcutis Biotherapeutics' Short-term Investments stood at $355.9 million in 2022, then sank by 48.46% to $183.5 million in 2023, then decreased by 14.63% to $156.6 million in 2024, then climbed by 13.7% to $178.1 million in 2025, then advanced by 6.27% to $189.2 million in 2026.
• Business Quant data shows ARQT's Short-term Investments at $189.2 million in Q1 2026, $178.1 million in Q4 2025, and $143.9 million in Q3 2025.